Arkema: Statement About the Number of Shares and Voting Rights in Compliance With the Article L.233-8 II of the French Commercial Code and the Article 223-16 of the Financial Markets Authority (AMF-Autorité Des Marchés Financiers)

Why It Matters

Accurate share and voting‑right data are critical for investors assessing control and potential dilution, and the filing reinforces Arkema’s adherence to French corporate‑governance standards.

Key Takeaways

• Total shares: 76,060,831 as of Feb 28 2026
• Voting rights total 95,362,268 including company holdings
• Excluding company, voting rights equal 94,964,128
• Disclosure meets French Commercial Code and AMF rules
• Enhances shareholder transparency and governance oversight

Pulse Analysis

French listed companies are required to publish detailed share and voting‑right figures under article L.233‑8 II of the Commercial Code and article 223‑16 of the AMF regulations. These rules aim to provide market participants with a clear view of a company’s equity distribution, preventing hidden concentrations of power and ensuring that voting influence is transparent. By adhering to these statutes, firms like Arkema demonstrate compliance with the rigorous governance framework that underpins France’s capital markets.

Arkema’s latest filing reveals 76,060,831 issued shares and a total voting‑right pool of 95,362,268, of which 398,140 voting rights are held by the company itself. The remaining 94,964,128 voting rights belong to external shareholders, indicating that the firm’s own holdings represent a modest fraction of overall voting power. This granular breakdown helps investors gauge the potential impact of any future share issuances, buybacks, or strategic transactions on control dynamics.

For investors and analysts, such disclosures are more than a regulatory checkbox; they are a signal of corporate transparency and governance quality. Clear voting‑right data supports accurate valuation models, especially when assessing takeover risk or shareholder activism potential. Moreover, consistent compliance enhances market confidence, potentially lowering the cost of capital for Arkema and reinforcing its reputation as a well‑governed player in the diversified chemicals sector.